



Investigation of the mechanisms of action behind Electromotive Drug Administration (EMDA)

Bor Kos¹, Juan Luis Vásquez², Damijan Miklavčič¹, Gregers G.G. Hermann³ and Julie Gehl²

¹ Faculty of Electrical Engineering, University of Ljubljana, Ljubljana, Slovenia

² Department of Oncology, Copenhagen University Hospital Herlev, Copenhagen, Denmark

³ Department of Urology, Copenhagen University Hospital Frederiksberg, Copenhagen, Denmark

ABSTRACT

Objective. Bladder cancer is a cause of considerable morbidity worldwide. Electromotive Drug Administration is a method that combines intravesical chemotherapy with local electric field application. Electroporation has been suggested among other mechanisms as having a possible role in the therapy, so the goal of the present study was to investigate the electric fields present in the bladder wall during the treatment to determine which mechanisms might be involved.

Material and Methods. Electromotive Drug Administration involves applying intravesical mitomycin C with direct current of 20 mA delivered through a catheter electrode for 30 min. For numerical electric field computation we built a 3-D nonhomogeneous patient specific model based on CT images and used finite element method simulations to determine the electric fields in the whole body.

Results. Results indicate that highest electric field in the bladder wall was 37.7 V/m. The mean electric field magnitude in the bladder wall was 3.03 V/m. The mean magnitude of the current density in the bladder wall was 0.61 A/m².

Conclusions. The present study shows that electroporation is not the mechanism of action in EMDA. A more likely explanation of the mechanism of action is iontophoretic forces increasing the mitomycin C concentration in the bladder wall.

Submitted 27 March 2016

Accepted 11 July 2016

Published 24 August 2016

Corresponding author

Bor Kos, bor.kos@fe.uni-lj.si

Academic editor

Cheorl-Ho Kim

Additional Information and
Declarations can be found on
page 9

DOI 10.7717/peerj.2309

© Copyright
2016 Kos et al.

Distributed under
Creative Commons CC-BY 4.0

OPEN ACCESS

Subjects Biophysics, Drugs and Devices, Oncology, Radiology and Medical Imaging, Urology

Keywords Bladder cancer, Mitomycin C, Electromotive Drug Administration, Electroporation

INTRODUCTION

Bladder cancer is a cause of considerable morbidity and mortality worldwide. The intensive care and treatment of bladder cancer represents a considerable burden to patients and society (*Botteman et al., 2003*). Intravesical therapy has been used to maximize the exposure of bladder tumors to the drug, while limiting systemic effects and toxicity. Mitomycin C (MMC) is the most widely used drug for intravesical irrigation in low and intermediate risk tumors (*Bouffieux et al., 1995; Sylvester, Oosterlinck & Van der Meijden, 2004*), while Bacillus Calmette-Guérin (BCG) is recommended for high-risk tumors (*Sylvester, Van der Meijden & Lamm, 2002; Shelley et al., 2004; Böhle & Bock, 2004*). Intravesical chemotherapy with MMC is used immediately after transurethral resection of tumor (TURBT) to treat

circulating tumor cells that can reimplant at other sites of the bladder, or as an ablative effect on residual tumour cells at the resection site (Pan et al., 1989; Brocks, Büttner & Böhle, 2005). MMC is also used in series of 8-weekly intravesical irrigations for patients with high risk of recurrence (Tolley et al., 1996; Sylvester, Oosterlinck & Witjes, 2008).

MMC migrates poorly deeper into the lamina propria, which may explain MMC's poor efficacy treating T1 tumors invading this layer of the mucosa. Electrokinetic forces may accelerate and increase drug delivery across the urothelium. Electromotive Drug Administration (EMDA) is a method that combines intravesical chemotherapy with local electric field application. Di Stasi et al. (1999) suggested in an *ex vivo* model that concentrations of MMC may be increased in all the layers of the bladder wall, when the drug was delivered with EMDA. Clinical studies where EMDA/MMC was applied showed lower recurrence rates than MMC alone, and equivalent efficacy for the treatment of high-risk bladder tumors when compared to BCG (Di Stasi et al., 2003; Di Stasi et al., 2006) with few side effects noted. Thus EMDA method seems safe and effective.

It has been proposed that EMDA leads to the combination of several electro-molecular interactions; iontophoresis, electroosmosis/electrophoresis, and electroporation (Di Stasi et al., 1997). All these phenomena may potentially be responsible for electromotive transport of drug molecules through biological membranes and into the underlying tissue when the electric field is applied. EMDA method is being used experimentally in relatively few centers, possibly due to the fact that the mechanisms of action are poorly understood. However, the actual worldwide shortage of BCG has led to the use of alternative methods and increased use of EMDA/MMC. Consequently there is a need to further elucidate the mechanisms of action of this treatment, which led to the present study.

The objective of this study is to perform calculations of the electric field present in the bladder wall during EMDA treatments, and in that way estimate what biological mechanisms may be at play when the tissue is exposed to this particular electric field.

MATERIALS AND METHODS

The main goal of the following steps was to build an *in-silico* representation of a human body during the delivery of an EMDA treatment. This was done by reconstructing the anatomical shape of the body and the relevant tissues from CT images and then using a computational approach to determine the relevant electric quantities in the tissues: electric field and current density. These quantities were then analyzed to get an insight into the possible mechanisms of EMDA.

Delivery setup

EMDA is administered by a battery powered current generator (Physionizer[®]) that delivers a controlled electric current of 0–30 mA/0–55 V DC, which is passed between electrodes: (1) the active intravesical electrode is a silver spiral integrated to the tip of a specifically designed transurethral catheter, (2) two dispersive ground electrodes, placed in the lower abdominal skin. The operator sets the active electrode's polarity and current intensity on the generator.

When applying intravesical EMDA with MMC for non-muscle invasive bladder cancer, the catheter is inserted into the bladder followed by instillation of 40 mg of MMC in 50 ml




Figure 1 Schematic illustration of the EMDA application system. (A) Numbers indicate the electrodes: 1, helical bladder catheter electrode; 2, abdominal patch electrodes. (B) The catheter is inserted in the urinary bladder and connected to the current generator.

0.9% NaCl solution. The catheter and the ground electrodes are connected to the generator, and the active electrode is set to positive polarity. The generator gradually increases the current to a predetermined level (20–25 mA) at a rise rate of 50 mA/s. The total treatment time is 30 min. This setup is shown in Fig. 1.

Segmentation of medical images

Different tissues have different electrical properties. To be able to accurately compute the electrical quantities in the body we need to differentiate between these tissues and assign them their appropriate properties. Abdominal CT images of a patient treated with EMDA were segmented into the following tissues (bladder wall, bladder lumen, small intestine, prostate, muscle, bone, fat, and internal air) using ITK-Snap version 2.4 (Yushkevich et al., 2006). The patient was a participant in a clinical trial where EMDA was tested, and the Ethics Committee of the Capital Region of Denmark approved this trial (study number H-1-2012-050). As the current study is not part of the clinical trial, permission for the use of the CT images was obtained from the patient orally.

A radiologist verified the segmentation. The pixel size in the segmentation was 0.781 mm, while the slice separation was 3 mm. In total 72 slices were segmented, corresponding to 14 slices below the bladder and 3 slices above the top edge of the external electrodes.

3-D model building

A 3-D model of the patient's anatomy was constructed in COMSOL Multiphysics version 5.2 (Comsol AB, Stockholm, Sweden). The outside of the body was constructed using a planar contour method using an algorithm written in Matlab (Mathworks, Natick, MA, USA) (Sel, Lebar & Miklavcic, 2007). The tissues of the interior of the body were taken into

Table 1 Electrical conductivity values used in the computational model.

Tissue	Conductivity [S/m]	Reference
Bladder wall	0.2	<i>Gabriel, Lau & Gabriel (1996a), Gabriel, Lau & Gabriel (1996b)</i>
Bladder lumen	1.5	<i>Stogryn (1971)</i>
Prostate	0.41	<i>Gabriel, Lau & Gabriel (1996a), Gabriel, Lau & Gabriel (1996b)</i>
Fat	0.012	<i>Gabriel, Lau & Gabriel (1996a), Gabriel, Lau & Gabriel (1996b)</i>
Muscle	0.2	<i>Gabriel, Lau & Gabriel (1996a), Gabriel, Lau & Gabriel (1996b)</i>
Intestines	0.4	<i>Gabriel, Lau & Gabriel (1996a), Gabriel, Lau & Gabriel (1996b)</i>
Bone	0.02	<i>Gabriel, Lau & Gabriel (1996a), Gabriel, Lau & Gabriel (1996b)</i>

account by building a spatial conductivity matrix in Matlab by assigning conductivity values based on the segmentation (*Aström et al., 2009*). The tissue properties were taken from the literature (*Gabriel, Lau & Gabriel, 1996a; Gabriel, Lau & Gabriel, 1996b*) and the actual values used are reported in [Table 1](#). The conductivity of the saline used for bladder irrigation was also taken from the literature (*Stogryn, 1971*). Electrodes were added by CAD modelling directly in COMSOL based on the dimensions of the actual electrodes. The balloon of the catheter (12 mm diameter) was placed right above the bladder neck. The catheter electrode consists of a helical wire with a diameter of 0.4 mm and 20 turns. The major radius of the helix was 1.25 mm, while the turn pitch was 1.6 mm; therefore, the total combined length of the electrode is 32 mm. This electrode shape limits the intensity of the electric field and current density around the electrode. The outer electrodes were modelled as a patch with outer dimensions of 5 × 7 cm. The resulting model is shown in [Fig. 2](#). The catheter balloon was modelled as a perfect insulator, so it was excluded from the computation.

Computational setup

We used the stationary finite element method solvers in COMSOL Multiphysics to solve the Laplace equation for electric potential in the 3-D model of the patient's anatomy. The model was discretized using a free tetrahedral mesh, which consisted of 2,779,405 elements. We used the conductive media DC interface in COMSOL Multiphysics to run a static simulation of the applied current density and electric fields inside the body. The electrodes were driven with a current-source terminal boundary condition, while the skin was taken into account only at the skin-electrode interface, by using a built-in thin resistive layer boundary condition in COMSOL. The results were extracted on a grid with data points positioned at the centers of the image elements in the original anatomical CT scans.

RESULTS

Global quantities

Since the electrodes were driven by a current source (20 mA), it is possible to compute the resulting electrode voltages with the data from the manufacturer's specifications. The voltage between the two electrodes was 13.1 V, which is within the generator specification and corresponds well to the expected voltage. Unfortunately, the generator does not specify




Figure 2 3-D model with electrodes and different tissues. (A–C) sagittal, coronal and axial views. (D) rotated 3D view. The abdominal and bladder electrodes are indicated. In all panels, the bladder, intestine, prostate and internal air are shown, but clipped to only half of the model for clarity.

the output voltage at the time of the treatment so the exact value used in the treatment is not available for the validation of the model.

Applied fields in the body

Electric fields in the whole body were extracted. The highest magnitude of electric field in the simulations was 271 V/m, in the subcutaneous fat tissue near the surface electrodes. The maximum values in the bladder wall were 71.9 V/m. The mean and SD of electric field magnitude in the bladder wall were 6.0 V/m and 7.1 V/m, respectively.

The largest current density was found around the catheter electrode: 134 A/m². The largest current density in the bladder wall was 14.4 A/m². Mean current density in the bladder wall was 1.2 A/m², with the standard deviation being 1.4 A/m². The highest current density in all other tissues was 35.6 A/m², however this value was found in a single voxel and may be due to numerical error. The current density is mostly perpendicular to the bladder, although the current density is much higher at the anterior part than at the posterior as would be expected based on electrode positioning [Fig. 3](#).

DISCUSSION

Based on the values of electric fields, we can conclude that electroporation is highly unlikely to be the predominant mechanism of action in EMDA. Typically, electroporation occurs at electric field strengths that are above 40,000 V/m ([Cemazar et al., 1998](#); [Miklavcic et al., 1998](#); [Gehl et al., 1999](#); [Pucihar et al., 2011](#)) also on urothelial cells ([JL Vásquez, 2013](#), unpublished data), while the electric fields reached established by EMDA are well below even 100 V/m. Although electroporation thresholds decrease with increasing duration of electric field application, the lowest reported in the literature is above 10,000 V/m for 100 ms pulse duration ([Pucihar et al., 2011](#)). The highest amplitude of the induced transmembrane voltage (ITV) according to Schwann's equation ([Schwan, 1957](#)) is determined by the equation $ITV_{Max} = 1.5ER$, where E is the electric field strength to which the cell of radius R is exposed. Based on the size of the cells used by Pucihar et al. in their experiments, the highest transmembrane voltage at 100 ms pulses was approximately 150 mV. The superficial layer of the bladder contains polyhedral cells of up to 250 μm in diameter ([Khandelwal, Abraham & Apodaca, 2009](#)). Given the value of the electric field in the bladder, the highest expected ITV during the treatment is 14 mV or lower, which is well within physiological values of transmembrane potential. The other layers of the bladder contain much smaller cells, which would result in even lower ITV.

Typically, iontophoresis setups for trans-dermal drug delivery use current densities in the range of 0.1–0.5 mA/cm² ([Kalia et al., 2004](#)), which is equal to 1–5 A/m² and therefore very close to the values produced by our model. The values of current density in the bladder wall support the hypothesis, that iontophoresis is involved in EMDA, and that is likely to be the contributing factor for reducing recurrence, due to the increase of the drug concentration near the point of excision.

Due to the placement of the abdominal electrodes on the front part of the abdominal wall, the predominant direction of the current flow is towards the front, as can be seen




Figure 3 Visualization of the current in the whole body and the current density in the bladder wall. (A) Current lines from the bladder electrodes to the abdominal patch electrodes. (B) Surface plot of the current density on the bladder wall in the sagittal view (from the left side). (C) Surface plot of the current density in a coronal view (from the front). The current density is markedly higher in the upper anterior bladder wall in comparison to the posterior and lower bladder walls.




Figure 4 Electric field and current density in the bladder wall. The figure shows an axial slice at the vertical center of the bladder wall. Both panels show the same slice. The panels show: (A) Electric field, (B) Current density.

in Figs. 3 and 4. This means that the current density of the posterior bladder wall could be below the current density required for efficient iontophoretic flow, i.e., the treatment would be more successful for tumors located on the front half of the bladder than for the back half.

The present study is limited by the fact that it is based on a single patient, and that the exact positioning of the intravesical electrode during the treatment is unknown. Additionally, the variability between patients would affect the values of electrical quantities in the tissue. However, even with these variations, the difference in the electric fields and current density would not be so great to change our findings.

Our study shows that electroporation is *not* the mechanism of action in EMDA. However, electroporation combined with chemotherapy (electrochemotherapy) is a novel and interesting treatment modality in use for the treatment of cutaneous tumors and in clinical trials for tumors in internal organs (*Campana et al., 2009; Matthiessen et al., 2011; Edhemovic et al., 2011; Miklavčič et al., 2014*). Also for bladder cancer, there are interesting perspectives for electrochemotherapy, both using MMC and cisplatin (*Vásquez, Gehl & Hermann, 2012; Vásquez et al., 2015*). These data on cisplatin used in electrochemotherapy experiments may give inspiration for new advances in iontophoretic drug delivery.

CONCLUSION

Based on numerical computational modelling based on realistically dimensioned models of EMDA treatment, we suggest that iontophoretic forces are predominant in this treatment. Electrode placements could mean that the anterior wall of the bladder receives a higher treatment field than other parts of the bladder. Also, due to the presence of a small air pocket in the bladder, the location directly above the air pocket receives a reduced treatment. Based on the numerical results alternate electrode positions should be considered if the original location of the excised tumor is not on the anterior bladder wall.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

The authors received no funding for this work.

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Bor Kos conceived and designed the experiments, performed the experiments, analyzed the data, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.
- Juan Luis Vásquez conceived and designed the experiments, analyzed the data, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.
- Damijan Miklavčič wrote the paper, reviewed drafts of the paper.
- Gregers G.G. Hermann analyzed the data, wrote the paper, reviewed drafts of the paper.
- Julie Gehl conceived and designed the experiments, wrote the paper, reviewed drafts of the paper.

Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The patient was a participant in a clinical trial where EMDA was tested and the Ethics Committee of the Capital Region of Denmark approved this trial (study number H-1-2012-050).

As the current study is not part of the clinical trial, permission for the use of the CT images was obtained from the patient orally.

Data Availability

The following information was supplied regarding data availability:

Kos, Bor; Luis Vásquez, Juan; Miklavcic, Damijan; G Hermann, Gregers; Gehl, Julie (2016): Investigation of the mechanisms of action behind Electromotive Drug Administration (EMDA). Figshare <https://dx.doi.org/10.6084/m9.figshare.3118759.v1>.

REFERENCES

- Aström M, Zrinzo LU, Tisch S, Tripoliti E, Hariz MI, Wårdell K. 2009.** Method for patient-specific finite element modeling and simulation of deep brain stimulation. *Medical and Biological Engineering and Computing* 47:21–28 DOI [10.1007/s11517-008-0411-2](https://doi.org/10.1007/s11517-008-0411-2).
- Böhle A, Bock PR. 2004.** Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. *Urology* 63:682–686 DOI [10.1016/j.urology.2003.11.049](https://doi.org/10.1016/j.urology.2003.11.049).
- Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. 2003.** The health economics of bladder cancer: a comprehensive review of the published literature. *Pharmacoeconomics* 21:1315–1330 DOI [10.1007/BF03262330](https://doi.org/10.1007/BF03262330).
- Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M, Sylvester R. 1995.** Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. *The Journal of Urology* 153:934–941 DOI [10.1016/S0022-5347\(01\)67608-0](https://doi.org/10.1016/S0022-5347(01)67608-0).
- Brocks CP, Büttner H, Böhle A. 2005.** Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer. *The Journal of Urology* 174:1115–1118 DOI [10.1097/01.ju.0000168657.51551.49](https://doi.org/10.1097/01.ju.0000168657.51551.49).
- Campana L, Mocellin S, Basso M, Puccetti O, De Salvo G, Chiarion-Sileni V, Vecchiato A, Corti L, Rossi C, Nitti D. 2009.** Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. *Annals of Surgical Oncology* 16:191–199 DOI [10.1245/s10434-008-0204-8](https://doi.org/10.1245/s10434-008-0204-8).
- Cemazar M, Jarm T, Miklavcic D, Lebar AM, Ihan A, Kopitar NA, Sersa G. 1998.** Effect of electric-field intensity on electroporation and electrosensitivity

- of various tumor-cell lines *in vitro*. *Electro- and Magnetobiology* 17:263–272
DOI 10.3109/15368379809022571.
- Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, Attisani F, De Carolis A, Capelli G, Vespasiani G, Stephen RL. 2006.** Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. *The Lancet Oncology* 7:43–51
DOI 10.1016/S1470-2045(05)70472-1.
- Di Stasi SM, Giannantoni A, Massoud R, Dolci S, Navarra P, Vespasiani G, Stephen RL. 1999.** Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. *Cancer Research* 59:4912–4918.
- Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, Vespasiani G. 2003.** Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. *The Journal of Urology* 170:777–782 DOI 10.1097/01.ju.0000080568.91703.18.
- Di Stasi SM, Vespasiani G, Giannantoni A, Massoud R, Dolci S, Micali F. 1997.** Electromotive delivery of mitomycin C into human bladder wall. *Cancer Research* 57:875–880.
- Ethemovic I, Gadzije EM, Breclj E, Miklavcic D, Kos B, Zupanic A, Mali B, Jarm T, Pavliha D, Marcan M, Gasljevic G, Gorjup V, Music M, Vavpotic TP, Cemazar M, Snoj M, Sersa G. 2011.** Electrochemotherapy: a new technological approach in treatment of metastases in the liver. *Technology in Cancer Research and Treatment* 10:475–485.
- Gabriel S, Lau R, Gabriel C. 1996a.** The dielectric properties of biological tissues: II. Measurements in the frequency range 10 Hz–20 GHz. *Physics in Medicine and Biology* 41:2251–2269 DOI 10.1088/0031-9155/41/11/002.
- Gabriel S, Lau R, Gabriel C. 1996b.** The dielectric properties of biological tissues: III. Parametric models for the dielectric spectrum of tissues. *Physics in Medicine and Biology* 41:2271–2293 DOI 10.1088/0031-9155/41/11/003.
- Gehl J, Sorensen TH, Nielsen K, Raskmark P, Nielsen SL, Skovsgaard T, Mir LM. 1999.** *In vivo* electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. *Biochimica Et Biophysica Acta-General Subjects* 1428:233–240
DOI 10.1016/S0304-4165(99)00094-X.
- Kalia YN, Naik A, Garrison J, Guy RH. 2004.** Iontophoretic drug delivery. *Advanced Drug Delivery Reviews* 56:619–658 DOI 10.1016/j.addr.2003.10.026.
- Khandelwal P, Abraham SN, Apodaca G. 2009.** Cell biology and physiology of the uroepithelium. *American Journal of Physiology. Renal Physiology* 297:F1477–F1501
DOI 10.1152/ajprenal.00327.2009.
- Matthiessen LW, Chalmers RL, Sainsbury DCG, Veeramani S, Kessell G, Humphreys AC, Bond JE, Muir T, Gehl J. 2011.** Management of cutaneous metastases using electrochemotherapy. *Acta Oncologica* 50:621–629 DOI 10.3109/0284186X.2011.573626.
- Miklavcic D, Beravs K, Semrov D, Cemazar M, Demsar F, Sersa G. 1998.** The importance of electric field distribution for effective *in vivo* electroporation of tissues. *Biophysical Journal* 74:2152–2158 DOI 10.1016/S0006-3495(98)77924-X.

- Miklavčič D, Mali B, Kos B, Heller R, Serša G. 2014.** Electrochemotherapy: from the drawing board into medical practice. *Biomedical Engineering Online* **13**:29 DOI [10.1186/1475-925X-13-29](https://doi.org/10.1186/1475-925X-13-29).
- Pan JS, Slocum HK, Rustum YM, Greco WR, Gaeta JF, Huben RP. 1989.** Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder. *The Journal of Urology* **142**:1589–1593.
- Pucihar G, Krmelj J, Reberšek M, Napotnik TB, Miklavčič D. 2011.** Equivalent pulse parameters for electroporation. *IEEE Transactions on Bio-Medical Engineering* **58**:3279–3288 DOI [10.1109/TBME.2011.2167232](https://doi.org/10.1109/TBME.2011.2167232).
- Schwan HP. 1957.** Electrical properties of tissue and cell suspensions. *Advances in Biological and Medical Physics* **5**:147–209 DOI [10.1016/B978-1-4832-3111-2.50008-0](https://doi.org/10.1016/B978-1-4832-3111-2.50008-0).
- Sel D, Lebar A, Miklavcic D. 2007.** Feasibility of employing model-based optimization of pulse amplitude and electrode distance for effective tumor electropermeabilization. *IEEE Transactions on Biomedical Engineering* **54**:773–781 DOI [10.1109/TBME.2006.889196](https://doi.org/10.1109/TBME.2006.889196).
- Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. 2004.** Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. *BJU International* **93**:485–490 DOI [10.1111/j.1464-410X.2003.04655.x](https://doi.org/10.1111/j.1464-410X.2003.04655.x).
- Stogryn A. 1971.** Equations for calculating the dielectric constant of saline water (correspondence). *IEEE Transactions on Microwave Theory and Techniques* **19**:733–736 DOI [10.1109/TMTT.1971.1127617](https://doi.org/10.1109/TMTT.1971.1127617).
- Sylvester RJ, Oosterlinck W, Van der Meijden A. 2004.** A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. *The Journal of Urology* **171**:2186–2190, quiz 2435 DOI [10.1097/01.ju.0000125486.92260.b2](https://doi.org/10.1097/01.ju.0000125486.92260.b2).
- Sylvester RJ, Oosterlinck W, Witjes JA. 2008.** The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. *European Urology* **53**:709–719 DOI [10.1016/j.eururo.2008.01.015](https://doi.org/10.1016/j.eururo.2008.01.015).
- Sylvester RJ, Van der Meijden APM, Lamm DL. 2002.** Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. *The Journal of Urology* **168**:1964–1970 DOI [10.1016/S0022-5347\(05\)64273-5](https://doi.org/10.1016/S0022-5347(05)64273-5).
- Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J, Freedman LS, Grigor KM, Hall RR, Hargreave TB, Munson K, Newling DW, Richards B, Robinson MR, Rose MB, Smith PH, Williams JL, Whelan P. 1996.** The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. *The Journal of Urology* **155**:1233–1238 DOI [10.1016/S0022-5347\(01\)66226-8](https://doi.org/10.1016/S0022-5347(01)66226-8).
- Vásquez JL, Gehl J, Hermann GG. 2012.** Electroporation enhances mitomycin C cytotoxicity on T24 bladder cancer cell line: a potential improvement of intravesical

chemotherapy in bladder cancer. *Bioelectrochemistry* **88**:127–133

[DOI 10.1016/j.bioelechem.2012.08.001](https://doi.org/10.1016/j.bioelechem.2012.08.001).

Vásquez JL, Ibsen P, Lindberg H, Gehl J. 2015. *In vitro* and *in vivo* experiments on electrochemotherapy for bladder cancer. *The Journal of Urology* **193**:1009–1015

[DOI 10.1016/j.juro.2014.09.039](https://doi.org/10.1016/j.juro.2014.09.039).

Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, Gerig G. 2006. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. *NeuroImage* **31**:1116–1128

[DOI 10.1016/j.neuroimage.2006.01.015](https://doi.org/10.1016/j.neuroimage.2006.01.015).